نتایج جستجو برای: jak2 mutation

تعداد نتایج: 294733  

Journal: :The Journal of biological chemistry 2008
Alexandra Dusa Judith Staerk Joanne Elliott Christian Pecquet Hélène A Poirel James A Johnston Stefan N Constantinescu

Explaining the uniqueness of the acquired somatic JAK2 V617F mutation, which is present in more than 95% of polycythemia vera patients, has been a challenge. The V617F mutation in the pseudokinase domain of JAK2 renders the unmutated kinase domain constitutively active. We have performed random mutagenesis at position 617 of JAK2 and tested each of the 20 possible amino acids for ability to ind...

Journal: :Hepatology 2006
Massimo Primignani Giovanni Barosi Gaetano Bergamaschi Umberto Gianelli Federica Fabris Raffaella Reati Alessandra Dell'Era Paolo Bucciarelli Pier Mannuccio Mannucci

The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd-Chiari syndrome (BCS); indeed, conventional clinical and hematological parameters usually yield insufficient information. To assess the diagnostic contribution of the gain-of-function mutation V617F of the JAK2 gene, 93 pati...

2016
KATIA BORGIA BARBOSA PAGNANO MÁRCIA TORRESAN DELAMAIN MARIANA MUNARI MAGNUS JOSÉ VASSALLO CARMINO ANTONIO DE SOUZA DAIANE DE ALMEIDA IRENE LORAND-METZE

The association of chronic myeloid leukemia (CML) with other myeloproliferative neoplasms (MPNs), in particular with the V617F mutation in the Janus kinase 2 (JAK2) gene, is very uncommon, and there are only a few cases reported in the literature. In the present study, the case of a 73-year-old man with CML and persistent thrombocytosis, is reported. The patient achieved a complete cytogenetic ...

Journal: :Biochemical Society transactions 2013
Stefan N Constantinescu Emilie Leroy Vitalina Gryshkova Christian Pecquet Alexandra Dusa

The discovery of the highly prevalent activating JAK (Janus kinase) 2 V617F mutation in myeloproliferative neoplasms, and of other pseudokinase domain-activating mutations in JAK2, JAK1 and JAK3 in blood cancers, prompted great interest in understanding how pseudokinase domains regulate kinase domains in JAKs. Recent functional and mutagenesis studies identified residues required for the V617F ...

Journal: :Haematologica 2009
Joanne Elliott Yvonne Suessmuth Linda M Scott Krystyna Nahlik Mary Frances McMullin Stefan N Constantinescu Anthony R Green James A Johnston

JAK2 V617F, identified in the majority of patients with myeloproliferative neoplasms, tyrosine phosphorylates SOCS3 and escapes its inhibition. Here, we demonstrate that the JAK2 exon 12 mutants described in a subset of V617F-negative MPN cases, also stabilize tyrosine phosphorylated SOCS3. SOCS3 tyrosine phosphorylation was also observed in peripheral blood mononuclear cells and granulocytes i...

Journal: :Lancet 2008
Dani Bercovich Ithamar Ganmore Linda M Scott Gilad Wainreb Yehudit Birger Arava Elimelech Chen Shochat Giovanni Cazzaniga Andrea Biondi Giuseppe Basso Gunnar Cario Martin Schrappe Martin Stanulla Sabine Strehl Oskar A Haas Georg Mann Vera Binder Arndt Borkhardt Helena Kempski Jan Trka Bella Bielorei Smadar Avigad Batia Stark Owen Smith Nicole Dastugue Jean-Pierre Bourquin Nir Ben Tal Anthony R Green Shai Izraeli

BACKGROUND Children with Down's syndrome have a greatly increased risk of acute megakaryoblastic and acute lymphoblastic leukaemias. Acute megakaryoblastic leukaemia in Down's syndrome is characterised by a somatic mutation in GATA1. Constitutive activation of the JAK/STAT (Janus kinase and signal transducer and activator of transcription) pathway occurs in several haematopoietic malignant dise...

Journal: :Blood 2014
Elisa Rumi Daniela Pietra Cristiana Pascutto Paola Guglielmelli Alejandra Martínez-Trillos Ilaria Casetti Dolors Colomer Lisa Pieri Marta Pratcorona Giada Rotunno Emanuela Sant'Antonio Marta Bellini Chiara Cavalloni Carmela Mannarelli Chiara Milanesi Emanuela Boveri Virginia Ferretti Cesare Astori Vittorio Rosti Francisco Cervantes Giovanni Barosi Alessandro M Vannucchi Mario Cazzola

We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) carried an MPL (W515) mutation, and 53 (8.6%) had nonmutated JAK2, CALR, and MPL (so-called triple-...

2016
Yan Chen Fang Fang Yang Hu Qian Liu Dingfang Bu Mei Tan Liusong Wu Ping Zhu

OBJECTIVE LNK is an adapter protein negatively regulating the JAK/STAT cell signaling pathway. In this study, we observed the correlation between variation in LNK gene and the clinical type of myeloproliferative neoplasms (MPN). METHODS A total of 285 MPN cases were recruited, including essential thrombocythemia (ET) 154 cases, polycythemia vera (PV) 76 cases, primary myelofibrosis (PMF) 19 c...

2014
P Nauroy F Delhommeau F Baklouti

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of leukemias with defective regulation of myeloid stem cell proliferation. They include four distinct diseases: chronic myeloid leukemia, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). In 2005, four independent studies have concurred to the identification in MPN patients of a specific mutation...

2015
Jung-Sook Ha Yu-Kyung Kim

BACKGROUND Calreticulin (CALR) mutations were recently discovered in patients with myeloproliferative neoplasms (MPNs). We studied the frequency and type of CALR mutations and their hematological characteristics. METHODS A total of 168 MPN patients (36 polycythemia vera [PV], 114 essential thrombocythemia [ET], and 18 primary myelofibrosis [PMF] cases) were included in the study. CALR mutatio...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید